Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Sep
Source: Bse
Best Agrolife Limited (BESTAGRO)
Small CapPharma stocks · Small cap · NSE
Best Agrolife Limited operates in Agrochemicals, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result31 Jul, 12:52 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
60BullishSMA20 -6.4% / mo · RSI oversold · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 33
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
BESTAGROD candles · FIT view-9.8%Latest close ₹15.87 on 2026-10-21
Bar
-2.0%
RSI
30
MACD hist
-0.16
52W pos
16%
2026-10-21O ₹16.19H ₹16.19L ₹15.49C ₹15.87Vol 5.2L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
BESTAGRONifty PharmaNifty 500
- BESTAGRO
- +2.3%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +8.8 pp
Chart stats
21 Oct 2026- From 52W high
- -53.9%
- 52W range position
- 16%
- ATR (14)
- 4.9%
- Volume vs 20D
- 0.91x
- Avg traded value
- ₹0.9 Cr
- 20D price channel
- ₹15.5 - ₹18.9
₹34.4
₹12.3 - ₹34.4
₹0.8
Latest completed session
20-session average
27.4% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · WATCHLIST32
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent80
Revenue +3.9% · PAT +105.0% YoY
Technical
Bullish60
Price trend and sector-relative-strength timing.
Valuation
Legacy model-910.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence56
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 80/100Rev +4% YoY · PAT +105% YoY · margin expansion · +154% QoQ · operating leverage
Filed 30 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹396 Cr | +3.9% | +153.8% |
| EBITDA | ₹78 Cr | +69.6% | +388.9% |
| Operating margin | 20.0% | +800 bps | +3700 bps |
| PAT | ₹41 Cr | +105.0% | NDF |
| PAT margin | 10.3% | +510 bps | +3407 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 21.20
- P/B
- 0.82
- EV/EBITDA
- 6.18
- Market Cap
- 627.00Cr
Profitability
- ROE
- 1.11%
- ROCE
- 5.15%
- ROA
- 1.78%
- Dividend Y
- 0.56%
Growth (CAGR)
- Revenue 5Y
- 7.00%
- EPS 5Y
- -26.00%
- Revenue 3Y
- -10.00%
- EPS 3Y
- -65.00%
Balance Sheet
- Debt/Equity
- 0.58
- Interest Coverage
- 2.40×
- Altman Z
- 2.20
- Book Value
- 21.70
Cash Flow
- FCF Yield
- 15.63%
- FCF Positive Y
- 3/5
- OCF
- 97.00 Cr
- EPS TTM
- 0.84
Shareholding
- Promoter Hold
- 50.44%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 24%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 396+153.8% vs prev
Net Profit
₹ CrLatest: 41.0+210.8% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 30. Wait for confirmation.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- Recent golden cross (SMA50 crossed above SMA200).
- SMA20 falling (~6.8% over last month) — short-term momentum negative.
- RSI(14) at 30 — oversold zone; bounce conditions.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 54% off 52W high · 29% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
38
RS percentile
Stage 1 Base / Transition
1M return
-14.4%
3M return
+2.3%
6M return
-13.2%
1Y return
-28.2%
RS 1D
+3
RS 20D
-18
Sector rank
#1
Industry rank
-
Stage evidence
- Price is within 7.0% of the 30-week proxy.
- The 30-week proxy changed +1.4% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
unranked
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 67.94+0.86%
RS vs Nifty 50068
Valuation & peers
U-Score 32 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 32 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation12/30
Growth3/25
Quality0/20
Balance Sheet7/15
Cash Flow7/10
Piotroski
6/9 (+3)
Penalties
0
Raw sum
32
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
32/100 · legacy band WATCHLIST
Positive drivers
- FCF yield is supportive at 15.6%.
- Cash flow contributes 7/10 to the score.
- Balance sheet contributes 7/15 to the score.
Main drags
- Fair-value margin of safety is negative at -910.2%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Growth is weaker at 3/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
21.2
PB
0.8
EV/EBITDA
6.2
ROE
1.1%
ROCE
5.2%
FCF Yield
15.6%
Debt/Equity
0.6
MoS
-910.2%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE.
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
32
Previous: 32
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-910.2%
Previous: -910.7%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
31
31
31
31
31
31
31
31
31
31
32
32
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹20.25
+21.6% MoS
Growth-justified P/E
1.9
Growth-justified Value
₹1.57
-910.2% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
ADVANCE
Small
Advance Agrolife Limited
Agrochemicals
match 169
40
29.0
29.1%
-152%
WATCHLIST
CLSL
SME
Crop Life Science Ltd.
Agrochemicals
match 158
34
16.8
8.1%
+61%
WATCHLIST
HERANBA
Small
Heranba Industries Limited
Agrochemicals
match 148
16
—
-9.7%
—
OVERVALUED
SHIVALIK
Small
Shivalik Rasayan Limited
Agrochemicals
match 145
24
44.0
2.2%
-729%
OVERVALUED
DHARMAJ
Small
Dharmaj Crop Guard Limited
Agrochemicals
match 144
48
15.0
13.3%
+65%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Best Agrolife Limited operates in Agrochemicals, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
56Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 18th percentile of the scored universe and 13th percentile within Pharma. Main check: results consistency is weak at 12/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
62 docs text-extracted · 27 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
18th percentile
overall median 67 · Pharma: 13th pctile, median 70 · Small: 20th pctile, median 66
Evidence depth
Financial-only
62 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
65
acceptable · leverage and solvency
Discipline
30
weak · capital discipline
Results
12
weak · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is 14.3%.
Trust risks
- ▸ROCE is low at 5.2%.
- ▸ROE is low at 1.2%.
- ▸ROCE trend is -6.2%.
- ▸1/4 latest quarters had positive YoY revenue growth.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Best Agrolife Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
Annual report
Business Responsibility and Sustainability Reporting (BRSR) 4 Sep - Best Agrolife submitted its FY 2025-26 BRSR as part of the annual report.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.